Carlyle Group Inc.
Institutional investor · Portfolio as of Q3 2025
Top Holdings17 positions
STANDARDAERO INC | 152.7M | $4.2B | 96.1% | $27.12 | +0.63% | 4 qtrssince 2024-Q4 | Unchanged 0 |
PONY AI INC SPONSORED ADS | 2.4M | $53.1M | 1.2% | $15.25 | +48.98% | 4 qtrssince 2024-Q4 | Unchanged 0 |
PHATHOM PHARMACEUTICALS INC | 3.5M | $41.1M | 0.9% | $7.87 | +43.88% | 11 qtrssince 2023-Q1 | Unchanged 0 |
SPRUCE BIOSCIENCES INC COM NEW | 2.9M | $24.8M | 0.6% | $9.70 | 0.00% | 1 qtr | New 59 |
INVITATION HOMES INC | 477,500 | $14M | 0.3% | $27.25 | +2.95% | 11 qtrssince 2023-Q1 | Unchanged 0 |
GETTY IMAGES HOLDINGS INC | 6.2M | $12.3M | 0.3% | $5.55 | -64.32% | 12 qtrssince 2022-Q4 | Unchanged 0 |
CUBESMART | 220,500 | $9M | 0.2% | $32.92 | +15.16% | 13 qtrssince 2022-Q3 | Unchanged 0 |
FORWARD AIR CORP | 107,214 | $3.1M | 0.1% | $25.15 | +4.37% | 2 qtrssince 2025-Q2 | Unchanged 0 |
JASPER THERAPEUTICS INC | 1.1M | $2.5M | 0.1% | $18.80 | -86.76% | 11 qtrssince 2023-Q1 | Unchanged 0 |
| 2.9M | $2.4M | 0.1% | — | — | 11 qtrssince 2023-Q1 | Unchanged 0 | |
COMPLETE SOLARIA INC | 1.3M | $2.2M | 0.1% | $1.39 | +28.12% | 9 qtrssince 2023-Q3 | Decreased 0 |
Q32 BIO INC | 1.1M | $2.1M | 0.0% | $11.84 | -83.62% | 7 qtrssince 2024-Q1 | Unchanged 0 |
KRISPY KREME INC | 340,748 | $1.3M | 0.0% | $14.92 | -76.07% | 7 qtrssince 2024-Q1 | Unchanged 0 |
EXICURE INC | 281,636 | $1.1M | 0.0% | $13.76 | -71.65% | 11 qtrssince 2023-Q1 | Unchanged 0 |
ONKURE THERAPEUTICS INC | 269,895 | $742,211 | 0.0% | $8.27 | -67.71% | 4 qtrssince 2024-Q4 | Unchanged 0 |
N-ABLE INC | 93,732 | $731,110 | 0.0% | $13.07 | -38.10% | 7 qtrssince 2024-Q1 | Unchanged 0 |
NUCANA PLC | 133,333 | $618,665 | 0.0% | $510.00 | -99.25% | 6 qtrssince 2024-Q2 | New 37 |
Carlyle Group Inc. manages $4.3B across 17 positions as of Q3 2025. Top holdings: SARO (96.1%), PONY (1.2%), PHAT (0.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1.5/5.0.
Added 2 new positions, exited 5, trimmed 1. Top move: SPRB (NEW, conviction 59). Portfolio: $4.3B across 17 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR